EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 772 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer MOST POPULAR Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 Black In Cancer – That Cancer Conversation October 8, 2021 Improving cancer care for the LGBTQ+ community July 26, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Teclistamab Whipple Procedure for Pancreatic Cancer: How to Prepare and What to... The stories behind Teenage and Young Adult Cancer Awareness Month EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
